VRDN insider transaction filings
Viridian Therapeutics, Inc.\DE — 36 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen VRDN transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Tousignant Jennifer — Chief Legal Officer | Sale (S): 4,212 @ $24.50 · Option exercise (M): 10,000 @ $14.41 · Sale (S): 10,000 @ $24.50 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-08-18 | 4 | Tripuraneni Radhika — Chief Medical Officer | Option exercise (M): 40,000 @ $13.21 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | CAIN CHRISTOPHER W. — Director | Grant/award (A): 32,341 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Moses Jennifer K. — Director | Grant/award (A): 32,341 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Gheuens Sarah — Director | Grant/award (A): 32,341 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Kiselak Tomas — Director | Grant/award (A): 32,341 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Ajer Jeffrey Robert — Director | Grant/award (A): 32,341 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Morris Arlene — Director | Grant/award (A): 32,341 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II GP LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner | Purchase (P): 1,176,470 @ $17 | EDGAR |
| 2026-03-09 | 4/A | Harmon Seth — Chief Financial Officer | Tax withholding (F): 2,031 @ $30.19 | EDGAR |
| 2026-03-09 | 4/A | Beetham Thomas W. — Chief Operating Officer | Tax withholding (F): 3,048 @ $30.19 | EDGAR |
| 2026-03-09 | 4/A | Tousignant Jennifer — Chief Legal Officer | Tax withholding (F): 1,675 @ $30.19 | EDGAR |
| 2026-03-09 | 4/A | Mahoney Stephen F. — President and CEO, Director | Tax withholding (F): 7,408 @ $30.19 | EDGAR |
| 2026-03-04 | 4 | Tousignant Jennifer — Chief Legal Officer | Option exercise (M): 5,169 · Tax withholding (F): 1,724 @ $29.32 · Grant/award (A): 119,300 (derivative) @ $0 · Grant/award (A): 23,850 (derivative) @ $0 · Option exercise (M): 5,169 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Harmon Seth — Chief Financial Officer | Option exercise (M): 6,267 · Tax withholding (F): 2,091 @ $29.32 · Grant/award (A): 102,850 (derivative) @ $0 · Grant/award (A): 20,550 (derivative) @ $0 · Option exercise (M): 6,267 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Beetham Thomas W. — Chief Operating Officer | Option exercise (M): 9,409 · Tax withholding (F): 3,138 @ $29.32 · Grant/award (A): 176,550 (derivative) @ $0 · Grant/award (A): 35,300 (derivative) @ $0 · Option exercise (M): 9,409 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Mahoney Stephen F. — President and CEO | Option exercise (M): 18,357 · Tax withholding (F): 7,627 @ $29.32 · Grant/award (A): 559,600 (derivative) @ $0 · Grant/award (A): 111,900 (derivative) @ $0 · Option exercise (M): 18,357 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Tripuraneni Radhika — Chief Medical Officer | Grant/award (A): 95,800 (derivative) @ $0 · Grant/award (A): 19,150 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4/A | Harmon Seth — Chief Financial Officer | Holdings only — no transactions reported | EDGAR |
| 2026-03-04 | 4/A | Tousignant Jennifer — Chief Legal Officer | Holdings only — no transactions reported | EDGAR |
| 2026-01-02 | 4 | Tousignant Jennifer — Chief Legal Officer | Sale (S): 2,272 @ $31.16 | EDGAR |
| 2025-10-27 | 4 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II GP LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner | Purchase (P): 454,545 @ $22 | EDGAR |
| 2025-07-02 | 4 | CAIN CHRISTOPHER W. — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Kiselak Tomas — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Gheuens Sarah — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Moses Jennifer K. — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Ajer Jeffrey Robert — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Morris Arlene — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II GP LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner | Option exercise (M): 1,600 @ $7.80 · Option exercise (M): 12,500 @ $12.31 · Option exercise (M): 1,600 (derivative) @ $0 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-04-09 | 4 | Ajer Jeffrey Robert — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | Tripuraneni Radhika — Chief Medical Officer | Grant/award (A): 310,700 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | CAIN CHRISTOPHER W. — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Tousignant Jennifer — Chief Legal Officer | Grant/award (A): 124,072 (derivative) @ $0 · Grant/award (A): 20,679 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Mahoney Stephen F. — President and CEO, Director | Grant/award (A): 440,565 (derivative) @ $0 · Grant/award (A): 73,428 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Beetham Thomas W. — Chief Operating Officer | Grant/award (A): 225,814 (derivative) @ $0 · Grant/award (A): 37,636 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Harmon Seth — Chief Financial Officer | Grant/award (A): 150,407 (derivative) @ $0 · Grant/award (A): 25,068 (derivative) @ $0 | EDGAR |
Recent 8-K events — Viridian Therapeutics, Inc.\DE
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-28 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-05-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-05-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VRDN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →